After The Run Up There's Still Double Digit Return Potential For Johnson & Johnson
All those years of growth for Johnson & Johnson have grown the company into a $279 B behemoth in the healthcare industry. Johnson & Johnson is unlikely to continue providing double digit annual growth in the company mainly due to their large size.
Shares represented a good opportunity between late August and mid October when they traded in the low $90's. However, since then shares are now trading hands for $101.03. So what kind of returns could you expect if you buy shares today after the recent run-up.
Continue reading the quick Johnson & Johnson stock analysis on Seeking Alpha.
For more detailed analyses check out my Stock Analysis page.
Image sourced from JNJ.com